Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
The independent source for health policy research, polling, and news.
461 - 480 of 698 Results
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
Health insurers and pharmacy benefit managers are exploring how two legal provisions 鈥 which have been on the books for decades 鈥 could bring down the price tags of certain prescription medications.聽
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner discuss final action on bills in Congress to address the opioid epidemic and fund federal health agencies. They also look at new efforts by the Food and Drug Administration to crack down on teen nicotine use.
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there鈥檚 a twist involving an opioid treatment.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Alice Ollstein of Politico talk about how health issues will play in midterm elections, the Trump administration鈥檚 move that could penalize legal immigrants who use government aid programs, and other topics. Due to technical difficulties, the original discussion taped Sept. 27 at the 2018 Texas Tribune Festival could not be broadcast, so the panelists reconvened from Austin and Washington on Sept. 28.
The protection is a win for people who get their needed, legitimate drugs from overseas.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren't proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.
Federal officials are allowing the private insurance plans to use 鈥渟tep therapy鈥 for drugs administered by doctors. In step therapy, patients must first use cheaper drugs to see if they work before receiving more expensive options.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn't afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma鈥檚 pricing.
California legislators approved some significant health care proposals in their rush to meet the Friday end-of-session deadline. They tackled controversial topics, such as making abortion pills available on college campuses, and adopted measures countering Trump administration attacks on the Affordable Care Act.
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico answer listeners鈥 questions about health policy and politics.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
漏 2026 KFF